US 2004/0002451 A1 · Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing

Abstract

The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.

Claims1

Dependent claims

An improved pharmaceutical formulation comprising a PEGsTNF-R1, wherein said formulation demonstrates improved stability and decreased viscosity (<400 cP) at concentrations of at least 45 mg/ml.

Dependencies are inferred from the claim text.

Facts

Application

10/177,566Filed 20 Jun 2002

Published

1 Jan 2004

Term ends

Not estimatedThe source records don’t support an estimate.

Classification42 codes

A61K 38/1816
Growth factors; Growth regulators: erythropoietin [EPO]
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 38/1793
Receptors; Cell surface antigens; Cell surface determinants: for cytokines; for lymphokines; for interferons

Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing

Life of this patent

Abstract

Claims1

Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing

Life of this patent

Abstract

Claims1